New drug cocktail shows promise for tough lung cancer
NCT ID NCT04497584
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether combining two drugs, afatinib and prednisone, can help people with advanced squamous non-small cell lung cancer who have already tried other treatments. The goal was to see if the combination could slow cancer growth. The trial enrolled 12 adults and measured how long they lived without the cancer getting worse.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SQUAMOUS NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UT Southwestern Medical Center
Dallas, Texas, 75390, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a gentler chemo combo with delayed immunotherapy tame advanced lung cancer?
- New drug HDM2020 targets tough lung cancer in early trial
- Can a lighter chemo punch still knock out lung cancer when paired with immunotherapy?
- Researchers test if electronic health records can mimic Gold-Standard cancer studies
- New study digs into long-term survival data for advanced lung cancer patients on immunotherapy
- Immunotherapy plus chemo aims to extend lives in tough lung cancer